References
- Hutchinson L, Kirk R. High drug attrition rates--where are we going wrong? Nat. Rev. Clin. Oncol. 8(4), 189–190 (2011).
- Rubin EH, Gilliland DG. Drug development and clinical trials--the path to an approved cancer drug. Nat. Rev. Clin. Oncol. 9(4), 215–222 (2012).
- Kolb EA, Gorlick R, Reynolds CP et al. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr. Blood Cancer. 60(8), 1325–1332(2013).
- Peterson JK, Houghton PJ. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur. J. Cancer 40(6), 837–844 (2004).
- Wong H, Choo EF, Alicke B et al. Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin. Cancer Res. 18(14), 3846–3855 (2012).
- Santana VM, Zamboni WC, Kirstein MN et al. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin. Cancer Res. 9(2), 633–640 (2003).
- Leggas M, Stewart CF, Woo MH et al. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. Clin. Cancer Res. 8(9), 3000–3007(2002).
- Lock RB, Carol H, Maris JM et al. Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 60(7), E42–E45 (2013).
- Begley CG, Ellis LM. Drug development: Raise standards for preclinical cancer research. Nature 483(7391), 531–533 (2012).
- Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nat. Rev. Drug Discov. 10(9), 712 (2012).
- Houghton PJ, Morton CL, Tucker C et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr. Blood Cancer. 49(7), 928–940 (2007).
- Stegmaier K, Wong JS, Ross KN et al. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med. 2007;4(4), e122 (2007).
- Houghton PJ, Morton CL, Kang M et al. Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program. Pediatr. Blood Cancer 55(6), 1224–1226 (2010).
- DuBois SG, Krailo MD, Lessnick SL et al. Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children’s Oncology Group. Pediatr. Blood Cancer 52(3), 324–327 (2009).
- Houghton PJ, Cheshire PJ, Hallman JD et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol. 36(5), 393–403 (1995).
- Houghton JA, Cook RL, Lutz PJ, Houghton PJ. Melphalan: a potential new agent in the treatment of childhood rhabdomyosarcoma. Cancer Treat. Rep. 69(1), 91–96 (1985).
- Winter GE, Rix U, Lissat A et al. An integrated chemical biology approach identifies specific vulnerability of Ewing’s sarcoma to combined inhibition of Aurora kinases A and B. Mol. Cancer Ther. 10(10), 1846–56 (2011).
Website
- Pediatric Preclinical Testing Program (PPTP). http://pptp.nchresearch.org